Clinical Trials
56 trialsNCT05355701 2026-05-14
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT07426757 2026-04-07
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Pfizer
Phase 1 Not yet recruiting
NCT07340190 2026-04-02
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Novartis
Phase 1 Not yet recruiting
NCT04973163 2026-02-17
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07235748 2026-02-17
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Servier
Phase 1 Completed
NCT06575933 2026-02-11
MK-1084-009
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT06547164 2025-09-04
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
AstraZeneca
Phase 1 Completed
NCT04051827 2025-07-28
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Takeda
Phase 1 Completed
NCT01585623 2025-03-05
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Bristol-Myers Squibb
Phase 1 Completed
NCT04908176 2024-12-13
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
Phase 1 Completed
NCT05926180 2024-12-13
Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)
Dizal Pharmaceuticals
Phase 1 Completed
NCT02113813 2024-11-14
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Inc
Phase 1 Completed
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01296555 2024-07-31
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Terminated
NCT06360211 2024-07-03
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants
Bayer
Phase 1 Completed
NCT04887194 2024-05-08
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
Phase 1 Completed
NCT06348290 2024-04-04
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
Jemincare
Phase 1 Unknown
NCT04958226 2024-01-25
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT05395117 2023-12-13
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin
AstraZeneca
Phase 1 Completed
NCT04718740 2023-08-14
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02740712 2023-06-09
DDI
pharmaand GmbH
Phase 1 Completed
NCT04676035 2023-02-09
The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT05438303 2023-01-12
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
AstraZeneca
Phase 1 Completed
NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02688088 2022-10-18
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Eli Lilly and Company
Phase 1 Completed
NCT04727138 2022-05-16
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
Exscientia AI Limited
Phase 1 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT05028608 2022-02-25
A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.
Bayer
Phase 1 Completed
NCT04187456 2021-08-19
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body
AstraZeneca
Phase 1 Completed
NCT03291288 2021-05-14
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Daiichi Sankyo
Phase 1 Completed
NCT02244112 2021-02-21
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Amgen
Phase 1 Terminated
NCT01596647 2020-12-21
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02422589 2020-12-19
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
Novartis
Phase 1 Completed
NCT01456689 2020-12-17
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Novartis
Phase 1 Completed
NCT02520752 2020-12-10
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT03955939 2020-06-01
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
Eli Lilly and Company
Phase 1 Completed
NCT01393990 2020-03-24
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03301207 2019-12-05
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
Janssen Research & Development, LLC
Phase 1 Completed
NCT02686164 2019-08-28
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01287598 2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1 Completed
NCT03333824 2019-03-25
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT01209832 2019-03-18
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
Eli Lilly and Company
Phase 1 Terminated
NCT01517399 2019-02-12
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
Daiichi Sankyo
Phase 1 Completed
NCT03237416 2018-11-06
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Bayer
Phase 1 Completed
NCT03330990 2018-08-21
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Hoffmann-La Roche
Phase 1 Completed
NCT00258050 2017-12-06
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00880321 2017-11-13
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02082665 2017-07-24
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
GlaxoSmithKline
Phase 1 Completed